Recent review of the medical industry: Can Mindray Medical become Huawei in the medical and medical industry?

Recently, the news that Mind Medical, a domestic medical giant with an annual income of 9 billion yuan, submitted an IPO in the A-share market has become a hot topic in China's medical circle. At present, there are problems such as the monopoly of “foreign brand” and the high price of medical equipment in some areas of China. Therefore, the industry hopes that the medical equipment leader Mindray Medical can take the lead in upgrading its independent research and development capabilities and become the key to breaking the monopoly of the ocean. In addition, what are the hot spots in the medical industry in the near future? The editor of OFweek Medical Network will take you to review it.

News review

Can Mindray Medical become Huawei in China's medical device industry?

As one of the few R&D medical device companies in China that can compete with foreign counterparts in the field of high-end medical devices, Mindray has been highly hoped that it is even called “Huawei in China's medical device industry”.

However, Mindray’s annual income of 9 billion can only be said to have encountered a cake edge in the global high-end medical device market. According to public data, in 2015, Medtronic sales ranked first in the global medical device industry reached $28.8 billion. The size of Mindray is not yet a fraction of it. [ Original reading ]

In-depth interpretation of how the University of Science and Technology News deployment of the smart medical industry?

Recently, Tao Xiaodong, general manager of the Science and Technology Department of Science and Technology, and Lu Xiaoliang, executive deputy general manager, accepted the interview and answered the strategic significance of the deployment of artificial intelligence + medical care by Xunfei, the research and development of the related products and the main technical breakthroughs. In the process of encountering challenges and other issues, the following is the author's finishing of the interview content.

"China's total medical resources are insufficient, the distribution is irrational, and the quality resources are scarce. The core of the problem of difficult medical treatment and expensive medical treatment is the contradiction between supply and demand." At a press conference last year, Wang Pei'an, deputy director of the Health Planning Commission, explained this to the public. The existing problems in the medical industry in China. At the same time, in the case of serious shortage of resources, the precious time of medical staff has not been effectively utilized. On the one hand, doctors spend a lot of time every day on repeated work such as medical record writing and medical image reading. On the other hand, due to the lack of effective triage mechanism, many patients who doctors see are not good at themselves, resulting in serious waste of resources. It is precisely because of the pain point that the medical industry has been at the forefront of applying new technologies, and this time the outbreak of artificial intelligence technology is no exception. [ Original reading ]

IBM Watson Gene officially enters China: Introducing Watson Health Cognitive Intelligence Products

On June 21, 2017, Baiyang Intelligent Technology Co., Ltd. and IBM Watson Health Co., Ltd. jointly launched in Beijing, and Baiyang Intelligent Technology became the exclusive distributor of Watson for Genomics in China. Jointly promote the application of tumor genomic analysis, and provide pathologists and oncologists with recommendations for precise treatment based on oncogenic mutations.

This is the second Watson Health cognitive intelligence product introduced after Baiyang Intelligent Technology and IBM reached a strategic cooperation with Watson for Oncology three months ago. This deepening cooperation is expected to promote the application of cognitive intelligence in the medical field. " Accurate medicine " is moving forward. [ Original reading ]

PerkinElmer's $1.3 billion acquisition of self-improvement giant Ommon diagnosis

PerkinElmer's reputation in the medical and health field is not as big as in the field of industrial instruments, but as a giant across the industrial instrumentation and medical fields, his influence in the world is not small. PerkinElmer's sales revenue in 2016 was 2.11 billion US dollars, of which industrial instrument business income of more than 1.5 billion US dollars, in vitro diagnostic business of more than 600 million US dollars. It costs more than $1.3 billion to acquire Euromon, which has an annual sales income of $310 million, reflecting its ambition in the field of IVD! The purchase price is 4.2 times its income, which is very cost-effective!

On June 19, 2017, PerkinElmer announced that it has signed a definitive agreement to acquire EUROIMMUN Medical Laboratory Diagnostics (hereinafter referred to as: Europe). [ Original reading ]